Elanco Animal Health (NYSE:ELAN) Director Buys $936,000.00 in Stock

Elanco Animal Health Incorporated (NYSE:ELAN) Director Lawrence Erik Kurzius acquired 40,000 shares of Elanco Animal Health stock in a transaction dated Thursday, August 20th. The stock was purchased at an average cost of $23.40 per share, with a total value of $936,000.00. Following the completion of the purchase, the director owned 188,647 shares of the company’s stock, valued at approximately $4,414,339.80. This represents a 26.91% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Elanco Animal Health Price Performance

Shares of ELAN stock traded up $0.49 on Friday, hitting $24.05. 4,748,443 shares of the stock traded hands, compared to its average volume of 5,728,003. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.05 and a quick ratio of 1.10. Elanco Animal Health Incorporated has a 52 week low of $17.11 and a 52 week high of $27.98. The firm has a 50 day simple moving average of $24.56 and a two-hundred day simple moving average of $24.01. The firm has a market cap of $12.02 billion, a price-to-earnings ratio of -58.66, a PEG ratio of 1.47 and a beta of 1.67.

Elanco Animal Health (NYSE:ELAN) last issued its earnings results on Wednesday, August 5th. The company reported $0.34 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.07. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The company had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.31 billion. During the same quarter in the prior year, the firm posted $0.26 EPS. Elanco Animal Health’s quarterly revenue was up 10.2% compared to the same quarter last year. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. As a group, equities research analysts predict that Elanco Animal Health Incorporated will post 1.12 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on ELAN shares. Weiss Ratings upgraded shares of Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a research report on Friday, July 31st. UBS Group boosted their price target on shares of Elanco Animal Health from $31.00 to $33.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. TD Cowen increased their price objective on shares of Elanco Animal Health from $31.00 to $32.00 and gave the company a “buy” rating in a report on Thursday, June 18th. Morgan Stanley increased their price objective on shares of Elanco Animal Health from $23.00 to $26.00 and gave the company an “equal weight” rating in a report on Wednesday, July 22nd. Finally, JPMorgan Chase & Co. raised their price objective on Elanco Animal Health from $28.00 to $30.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Elanco Animal Health presently has a consensus rating of “Moderate Buy” and an average target price of $29.09.

Institutional Trading of Elanco Animal Health

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. NewEdge Advisors LLC increased its position in Elanco Animal Health by 133.7% during the fourth quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock valued at $25,000 after acquiring an additional 627 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in shares of Elanco Animal Health in the 2nd quarter worth about $38,000. Root Financial Partners LLC boosted its stake in shares of Elanco Animal Health by 50.7% during the 4th quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock worth $40,000 after purchasing an additional 592 shares during the period. Uniplan Investment Counsel Inc. purchased a new position in shares of Elanco Animal Health during the 4th quarter worth about $41,000. Finally, Torren Management LLC bought a new position in Elanco Animal Health during the 4th quarter valued at about $46,000. Hedge funds and other institutional investors own 97.48% of the company’s stock.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.